Cargando…

Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report

This article describes a patient who developed Harada disease-like uveitis after quadrivalent human papillomavirus (HPV4) vaccination and experienced resolution without any systemic treatment. To achieve this aim, a case report and a review of related literature on HPV vaccination causing uveitis we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Kangjie, Ding, Xinyi, Ni, Yingqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	HPV – Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920230/ https://www.ncbi.nlm.nih.gov/pubmed/34348578 http://dx.doi.org/10.1080/21645515.2021.1953349

Ejemplares similares

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Human papillomavirus vaccination at the first opportunity: An overview
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
por: Ellingson, Mallory K., et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Barriers and facilitators in uptake of human papillomavirus vaccine across English Canada: A review
por: Khan, Amal, et al.
Publicado: (2023)

Parents’ willingness to vaccinate their daughters with human papillomavirus vaccine and associated factors in Debretabor town, Northwest Ethiopia: A community-based cross-sectional study
por: Aragaw, Getie Mihret, et al.
Publicado: (2023)

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China
por: Yuan, Haowen, et al.
Publicado: (2023)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age
por: Zhao, Chao, et al.
Publicado: (2022)

Medical ethics principles underscore advocating for human papillomavirus vaccine
por: Healy, C. Mary, et al.
Publicado: (2022)

Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the National Immunization Program
por: Ujiie, Mugen
Publicado: (2022)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Parents’ stigmatizing beliefs about the HPV vaccine and their association with information seeking behavior and vaccination communication behaviors
por: McKenzie, Ashley Hedrick, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

How to make effective HPV vaccine recommendations starting at age 9
por: Brewer, Noel T., et al.
Publicado: (2023)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Descriptive epidemiology of age at HPV vaccination: Analysis using the 2020 NIS-Teen
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers
por: Lake, Paige, et al.
Publicado: (2023)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities
por: Coyne-Beasley, Tamera, et al.
Publicado: (2023)

The influence of political ideology on awareness of HPV and HPV vaccine among adults in the United States
por: Chido-Amajuoyi, Onyema Greg, et al.
Publicado: (2023)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China
por: Wu, Huamei, et al.
Publicado: (2023)

HPV vaccine knowledge, attitudes, and practices among New York State medical providers, dentists, and pharmacists
por: Fernandes, Annlynn, et al.
Publicado: (2023)

Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States
por: Meites, Elissa, et al.
Publicado: (2022)

An opportunity to increase human papillomavirus vaccination rates: Change the guidelines
por: Aragones, Abraham, et al.
Publicado: (2022)

Willingness to accept human papillomavirus vaccination in Jimma town, Ethiopia
por: Biyazin, Tsegaw, et al.
Publicado: (2022)

Individual, systemic and state factors associated with provider recommendation of HPV vaccination: Findings from NIS-Teen, 2020
por: Osaghae, Ikponmwosa, et al.
Publicado: (2023)

Multilevel perspectives on school-based opportunities to improve HPV vaccination among medically underserved adolescents: Beyond school entry mandates
por: Shin, Michelle B., et al.
Publicado: (2023)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s6an58nf4u3s19h1ug8saqm80v